A study of Gila monster venom helped start the revolution in weight-loss drugs. But scientists think that’s just the ...

Longhorn Vaccines and Diagnostics, a One Health company developing vaccines and diagnostic tools for global public health and zoonosis concerns, presented new data at the Union World Conference on ...

No. 11 / 2024 Zealand Pharma to participate in the Jefferies London Healthcare Conference Copenhagen, Denmark – Zealand ...

Ijeoma Uchegbu discusses nanomedicine's role in improving medication adherence and developing non-addictive pain relief ...

Researchers believe discovery will springboard research to make more tolerable, effective weight loss treatments accessible ...

High-dose LTI-03 (5 mg BID), a Caveolin-1 related peptide, reduced expression of multiple profibrotic proteins in both pathological basal-like cells and fibroblasts and decreased the expression of a ...

Tharimmune, Inc. (NASDAQ:THAR) (”Tharimmune” or the “Company”), a clinical-stage biotechnology company developing a portfolio of therapeutic candidates in inflammation and immunology, announced today ...

With particular utility in cancer therapies, this innovative platform is designed to enhance the delivery of therapeutic antibodies and peptides, which are often ... non-toxic profiles and the ability ...

Plus: How AI can make it easier to find drugs from nature and a study suggests Ozempic could treat alcoholism.

Professor Nancy Ip discusses her groundbreaking neuroscience research, focusing on neurotrophic factors and innovative ...

Early studies show a drug can effectively 'switch on' particular cells within the nervous system that play an important role ...